LungLifeAI™

8 April 2022

LungLife AI, Inc.
(the "**Company**" or "**LungLife**")

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company's website and have been posted to those shareholders who have opted out of electronic communications.

The documents are available here: https://investors.lunglifeai.com/

The Company's AGM will be held at 2:00 P.M. (BST) on 11 May 2022, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.

Following the easing of coronavirus (COVID-19) restrictions in the UK, the Board has made arrangements to enable shareholders to attend the Annual General Meeting in person. However, in light of the uncertainty as to any further COVID-19 measures that may be put in place by the UK Government and bearing in mind the inherent risk of large gatherings, the Company encourages shareholders to consider submitting their voting instructions in advance by appointing the Chairman of the meeting as their proxy, rather than attending and voting on the day. This will ensure that votes are registered in accordance with shareholders' wishes regardless of any restrictions or disruption around the Annual General Meeting and will also help protect the health and safety of shareholders, directors and other necessary attendees. Depending on the public health situation, we may impose additional procedures or limitations on attendees beyond any described in this Notice of the Annual General Meeting. The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. We will announce details of how to listen to the meeting remotely and any other significant changes to the meeting arrangements via RNS and on our website at https://investors.lunglifeai.com/

We strongly encourage you to vote by proxy, whether or not you plan to attend the Company's Annual General Meeting in person. Alternatively, you may register your votes on the resolutions of the Annual General Meeting by completing and returning the proxy form that accompanies the Notice in accordance with the instructions printed on the proxy form. Or by using the link www.signalshares.com and selecting LUNGLIFE AI, INC (You will need to log into your Signal Shares account or register if you have not previously done so. To register you will need your Investor Code, this is detailed on your share certificate or available from our Registrar, Link Group).

If your holding of Common Shares is by way of dematerialised depository interests representing underlying Common Shares ("Depository Interests"), you can vote through the CREST system or by returning a Form of Direction to the Depositary. Further instructions are set out in the Notes to the Notice of Annual General Meeting, available on the Company website.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable possible after the AGM.

For further information please contact:

LungLife AI, Inc.	**www.lunglifeai.com**
Paul Pagano, CEO	**Via Walbrook PR**
David Anderson, CFO	
Investec Bank plc (Nominated Adviser & Broker)	**Tel: +44 (0)20 7597 5970**
Daniel Adams / Virginia Bull / Cameron MacRitchie	
Walbrook PR Limited	**Tel: +44 (0)20 7933 8780** or **LungLifeAI@walbrookpr.com**

Paul McManus / Alice Woodings / Phillip Marriage   Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com